FitLife Brands reports record revenue of $6.3M in first quarter 2014

FitLife Brands, Inc. ("FitLife") (OTCBB: FTLF), an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed under the brand names NDS Nutrition Products™ ("NDS") (www.ndsnutrition.com), PMD® (www.pmdsports.com), SirenLabs® (www.sirenlabs.com) and CoreActive® (www.coreactivenutrition.com) today announced financial results for the first quarter ended March 31, 2014.

Highlights for the first quarter of 2014 include:

  • Record revenue of $6.3 million, a 4.5% increase in comparison with the prior year
  • Operating income increased 53.6% to $0.9 million versus the prior year quarter
  • Operating margin increased by more than 450 basis points to 14.6% as compared to Q1 2013
  • Record quarterly net income of $1.0 million versus $0.6 million during the same period last year
  • Diluted earnings per share of $0.12 for the quarter versus $0.07 for the comparable quarter

Revenue for the three months ended March 31, 2014 was $6.3 million as compared to $6.1 million for the comparable period in 2013, an increase of 4.5%. For the three month period ended March 31, 2014, the Company reported net income of $1.0 million, or $0.12 per share, versus net income of $0.6 million, or $0.07 per share, in the comparable period in 2013.

"We saw strong domestic demand particularly in the last month of the quarter, a portion of which was attributable to the inventory build-up by some of our customers in advance of our planned transition to GNC's centralized distribution platform. The move to this distribution platform is consistent with GNC's established vendor policies, reflecting our strong growth trend established over the last several years. We look forward to the continued expansion of this relationship," stated John Wilson, FitLife's Chief Executive Officer.

"Our international sales in the first quarter were approximately $500,000 less than the first quarter of 2013. This lower number was a result of the timing of our initial launch of our international sales in the first quarter of 2013 as well as different purchasing patterns in our international markets. We continue to anticipate year over year growth in our international markets for 2014. I am particularly happy about the increase in our operating margins and corresponding impact on profitability. We remain very excited about our business opportunities for 2014 and beyond and look to continue the expansion of our domestic and international distribution networks, including the recent introduction of our SirenLabs brand into Australia," concluded Mr. Wilson.

The Company's reviewed financial statements will be included in its Form 10-Q for the first quarter ended March 31, 2014, which the company intends to file with the Securities and Exchange Commission on or before May 15, 2014.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Helene and CVS land double whammy for 25,000 patients who survive on IV nutrition